Clearmind Medicine announced the successful treatment and follow-up of 18 participants in its ongoing Phase I/IIa clinical trial of CMND-100, a non-hallucinogenic drug candidate for Alcohol Use Disorder (AUD). The trial, conducted at multiple sites including Yale and Tel Aviv, aims to assess the safety and efficacy of CMND-100 in patients with moderate to severe AUD. The company also treated four additional patients recently at its Israeli site, highlighting strong trial progress. This milestone advances Clearmind's goal to develop an innovative therapy for AUD, addressing a significant unmet medical need.
The global automotive microcontrollers market is projected to grow from USD 15.49 billion in 2025 to USD 34.31 billion by 2035, at a CAGR of 8.28%. Growth is fueled by increasing adoption of advanced driver-assistance systems (ADAS), vehicle electrif...
Alpaca, a brokerage infrastructure startup, secured $435 million in funding to enter prime brokerage services, challenging traditional Wall Street firms. The company’s API supports 94% of US equities and powers tokenized stocks for Kraken. Alpaca’s t...
Raymond James Financial's rating was raised to "Buy" after positive investor event disclosures and a promising preview of its upcoming quarterly results. The company is expected to exceed earnings per share consensus for Q3 FY26, driven by strong per...
Bitcoin and Ethereum experienced combined outflows exceeding $59 million as traders moved funds into stablecoins like USDT and fiat currencies, signaling a cautious stance in the crypto market. This rotation reflects a short-term defensive strategy, ...
Whales have accumulated 70 million XRP over the past week, showing strong confidence despite XRP's price consolidating below resistance levels. The XRP Ledger surpassed 8 million activated accounts, indicating growing network adoption across payments...
